Previous Article | Next Article ![]()
J. Virol., Sep 1997, 6509-6516, Vol 71, No. 9
F Kirchhoff, S Pohlmann, M Hamacher, RE Means, T Kraus, K Uberla and P Di Marzio
The recent identification of coreceptors that mediate efficient entry of
human immunodeficiency virus type 1 (HIV-1) suggests new therapeutic and
preventive strategies. We analyzed simian immunodeficiency virus (SIV)
entry cofactors to investigate whether the macaque SIV model can be used as
an experimental model to evaluate these strategies. Similar to primary
HIV-1 isolates, a well-characterized molecular clone, SIVmac239, which
replicates poorly but efficiently enters into rhesus alveolar macrophages
and an envelope variant, SIVmac239/316Env, with an approximately
1,000-fold-higher replicative capacity in macrophages used the
beta-chemokine receptor CCR5 for efficient entry. The transmembrane portion
of 316Env allowed low-level entry into cells expressing CCR1, CCR2B, and
CCR3. A single amino acid substitution in the V3 loop of SIVmac239/316Env,
321P-->S, impaired the ability to enter into the T-B hybrid cell line
CEMx174 but had relatively little effect on entry into primary cells and
HOS.CD4 cells expressing CCR5. Although CEMx174 cells do not express CCR5,
most SIVmac variants entered this hybrid cell line efficiently but did not
enter the parental T-cell line CEM. It seems likely that CEMx174 cells
express an as-yet-unidentified, perhaps B-cell-derived cofactor which
allows efficient entry of SIVmac.
Copyright © 1997, American Society for Microbiology
Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry
Institute for Clinical and Molecular Virology, University of Erlangen- Nurnberg, Germany. fkkirchh@viro.med.uni-erlangen.de
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|